Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 443, 496-497 (5 October 2006) | doi:10.1038/443496a; Published online 4 October 2006
Open Innovation Challenges
-
Protect Enzyme from In Planta Degradation
A proposal for stable expression of an enzyme in corn seed is desired.
-
Efficient Chromosome Doubling: Plant Cell Division
The Seeker is looking for an efficient chromosome doubling method in plants and in particular, metho...
- More Challenges
- Powered by:
nature jobs
Team Leader for Analytical Development
- Novo Nordisk
- Bagsværd, Denmark
Sensory Scientist
- Philip Morris International (PMI)
- Neuchatel, Switzerland
Copycats gear up to dog biotech brands
Meredith Wadman
Abstract
Pressure is mounting on US regulators to create an approval track for generic versions of biotechnology drugs. Meredith Wadman reports.
Bruce Downey gets exasperated when he looks at how long people have been dithering about the right way to deal with generic copies of biotechnology drugs.Last month in Washington DC, this chief executive of Barr Pharmaceuticals, New Jersey, was speaking at a meeting of makers of generic drugs.
To read this story in full you will need to login or make a payment (see right).
